Shoshana Shendelman, Applied Therapeutics CEO/founder

Biotech pulls plans to file ac­cel­er­at­ed ap­proval af­ter FDA 'change in di­rec­tion' — shares plum­met

When the FDA lift­ed a clin­i­cal hold on Ap­plied Ther­a­peu­tics’ lead pro­gram in galac­tosemia last Feb­ru­ary, the New York biotech sig­naled that they were then on a smooth road to­ward an ac­cel­er­at­ed ap­proval, with plans to file an NDA in the third quar­ter of 2021.

Reg­u­la­tors, though, ap­par­ent­ly changed their mind.

Ap­plied has de­cid­ed to hold on sub­mit­ting an NDA for AT-007 as a treat­ment for galac­tosemia, the com­pa­ny dis­closed, fol­low­ing dis­cus­sions with the FDA in which the agency in­di­cat­ed that “clin­i­cal out­comes da­ta will like­ly be re­quired for ap­proval.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Recon Strategy

Boston, MA, USA